Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Debora Moreno
Observed names:
D. Moreno,
Daniel Moreno Miranda,
Débora Moreno
Institution:
Pontificia Universidad Católica de Chile
Observed institutions:
Universitat Autònoma de Barcelona,
Pontificia Universidad Católica de Chile,
Barcelona Biomedical Research Park,
Hospital Clínic de Barcelona,
Vall d'Hebron Hospital Universitari,
Vall d'Hebron Institute of Oncology
show all 6
ORCID:
0000-0001-9992-493X
Observed ORCID:
0000-0001-9992-493X
OpenAlex ID:
A5109357669
A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2013
·
Isabel Puig
, Irene Chicote
, et al.
·
Clinical Cancer Research
·
91
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
2023
·
Javier García-Corbacho
, Alberto Indacochea
, et al.
·
Cancer Immunology Immunotherapy
·
19
PDF
Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
2025
·
Javier García-Corbacho
, Alberto Indacochea
, et al.
·
Cancer Immunology Immunotherapy
·
3
PDF
Epidemiología Nacional del Cáncer Colorrectal en Chile: Tendencias de Incidencia y Sobrevida en la Población FONASA.
2026
·
Daniel Moreno Miranda
, María Inés Gaete Dañobeitía
, et al.
·
Revista de Cirugía
·
1
PDF
Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.
2015
·
Guillem Argilés
, Elena Élez
, et al.
·
Journal of Clinical Oncology
·
1
Molecular profiling in gynecologic cancer and matched targeted therapy: A step toward improving personalized medicine.
2014
·
Ana C. Garrido-Castro
, Guillem Argilés
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Figure 4 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
PDF
Supplementary Figure 3 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
PDF
Supplementary Table 2 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
PDF
Supplementary Table 1 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
Supplementary Figure 1 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
PDF
Supplementary Figure 2 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
PDF
Data from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
Data from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
Supplementary Figure 3 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2023
·
Isabel Puig
, Irene Chicote
, et al.
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
2023
·
Javier García-Corbacho
, Alberto Indacochea
, et al.
·
Cancer Immunology Immunotherapy
PDF
116P Real-world and in silico incidence of fibroblast growth factor receptor (FGFR) 1-4 molecular alterations across multiple cancer types
2021
·
L. Angelats
, A. Indacochea
, et al.
·
Annals of Oncology
Abstract B187: Prevalence of MET copy number variation, MET expression and MET related genomic alterations in all solid tumors pre-screening program. VHIO experience
2015
·
Analía Azaro
, Guillem Argilés
, et al.
·
Molecular Cancer Therapeutics
2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients
2015
·
T. Sauri
, T. Macarulla
, et al.
·
European Journal of Cancer
Knocking on molecular alterations in advanced gastric cancer (AGC).
2015
·
Fabricio Racca
, Cinta Hierro
, et al.
·
Journal of Clinical Oncology
Early drug development in advanced gynecologic cancer based on genetic tumor profiling.
2015
·
Ana C. Garrido-Castro
, Guillem Argilés
, et al.
·
Journal of Clinical Oncology
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
2015
·
Enrique Sanz-Garcia
, Elena Elez
, et al.
·
Journal of Clinical Oncology
Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).
2014
·
Maria Elena Elez Fernandez
, Guillem Argiles
, et al.
·
Journal of Clinical Oncology
Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.
2014
·
Ludmila Prudkin
, Claudia Aura
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
24
Citation count:
116
H-index:
3
I10-index:
2
Year
Topic
Type